Sunday, September 8

Browsing: Novartis Pharmaceuticals Corporation

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

Health December 11, 2023

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases…

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

Health October 7, 2023

First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic…

Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers

World July 12, 2023

Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials…

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Health March 27, 2023

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 …

What's Hot

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

Browsing: Novartis Pharmaceuticals Corporation

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

smartBreakfast Series 2024: llamada de atención para 2027

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

Must Watch

Levy Konigsberg Files Lawsuit on Behalf of 50 Men Who Were Sexually Abused as Juveniles at the New Jersey Training School

First Responders Action Group and The Independence Fund to Present All-Terrain Tracked Wheelchair to Former Las Vegas Law Enforcement Officer

SmartDry System Utilizes Secure AI Technology to Optimize Spray Drying

What's Hot

Browsing: Novartis Pharmaceuticals Corporation

Subscribe to Updates